Skip to main content
. Author manuscript; available in PMC: 2012 Feb 1.
Published in final edited form as: Kidney Int. 2011 Jun 8;80(4):423–430. doi: 10.1038/ki.2011.155

Table 2.

Median [interquartile range]of plasma disappearance parameters of iohexol studies for the training and validation datasets from the MACS and CKiD populations.

Training Dataset (2/3 random sample)
Validation Dataset (1/3 random sample)
MACS (n= 350) CKID (n= 546) p-valuea MACS (n= 177) CKiD (n= 274)
Iohexol injection (mg) 3180 [3151, 3243] 3190 [3156, 3223] 0.426 3185 [3127, 3223) 3192 [3160, 3228]
Fast area b (mg min/ml) 3.2 [2.6, 3.9] 5.7 [4.0, 8.1] <0.001 3.4 [2.8, 4.1] 5.3 [3.7, 8.2]
Slow areac (mg min/ml) 21.9 [18.6, 25.5] 107.6 [73.9, 156.2] <0.001 21.3 [18.7, 25.0] 97.5 [63.8, 142.8]
GFR0,2d (ml/min | 1.73 m2) 125.3 [105.5, 149.0] 45.3 [33.4, 59.2] <0.001 128.3 [110.0, 150.1] 47.7 [36.2, 63.6]
GFR2,2e (ml/min | 1.73 m2) 108.6 [93.8, 126.2] 42.9 [32.0, 54.8] <0.001 112.1 [96.3, 124.9] 45.4 [34.6, 58.6]

MACS, Multicenter Aids Cohort Study; CKiD, Chronic Kidney Disease in Children Cohort Study

a

Wilcoxon rank-sum test comparing MACS and CKiD in training dataset, bold indicates statistically significant (p< 0.05).

b

Based on plasma samples at 10 and 30 minutes after iohexol injection

c

Based on plasma samples at 120 and 240 for MACS and 120 and 300 for CKiD minutes after iohexol injection

d

(iohexol injection/ slow area) × (1.73 / BSA)

e

(iohexol injection/ total area) × (1.73 / BSA)